In a Parkinson's disease mouse model, paquinimod treatment downregulated the expression of inflammatory cytokines (IL‐6, IL‐1β and TNF‐α) and suppressed the TLR4/NF‐κB signalling pathway [43]. This evidence concerns the gene IL1B and Parkinson disease.